JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

Kodu・Aktsiate loetelu・VolitionRX Ltd

VolitionRX Ltd

Suletud

0.25 4.17

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.24

Max

0.25

Põhinäitajad
By Trading Economics
Sissetulek	936K -5.4M
Müük	221K 627K
Kasumimarginaal	-857.414
Töötajad	75
EBITDA	1.3M -4.2M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+800% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	30. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-14M 32M
Eelmine avamishind	-3.92
Eelmine sulgemishind	0.25

VolitionRX Ltd Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. veebr 2026, 17:25 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

9. veebr 2026, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

9. veebr 2026, 23:43 UTC

Market Talk

Gold Falls on Possible Technical Correction -- Market Talk

9. veebr 2026, 23:14 UTC

Market Talk

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

9. veebr 2026, 22:29 UTC

Market Talk

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

9. veebr 2026, 22:19 UTC

Market Talk

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

9. veebr 2026, 22:08 UTC

Market Talk

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

9. veebr 2026, 22:01 UTC

Tulu

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

9. veebr 2026, 21:59 UTC

Tulu

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

9. veebr 2026, 21:59 UTC

Tulu

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

9. veebr 2026, 21:58 UTC

Tulu

Friedman Industries 3Q Sales $168M >FRD

9. veebr 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

9. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. veebr 2026, 21:48 UTC

Tulu

Friedman Industries 3Q EPS 43c >FRD

9. veebr 2026, 21:17 UTC

Tulu

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

9. veebr 2026, 21:13 UTC

Market Talk

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

9. veebr 2026, 21:04 UTC

Tulu

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

9. veebr 2026, 20:30 UTC

Market Talk

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

9. veebr 2026, 20:02 UTC

Market Talk

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

9. veebr 2026, 19:42 UTC

Market Talk

Japan's Yield Curve Expected to Flatten -- Market Talk

9. veebr 2026, 19:31 UTC

Market Talk

Nike Seen Regaining Relevance With Consumers -- Market Talk

9. veebr 2026, 19:27 UTC

Market Talk

Gold Climbs Back Over $5,000/oz -- Market Talk

9. veebr 2026, 19:05 UTC

Market Talk

Nike Returns to List of Hottest Brands -- Market Talk

9. veebr 2026, 18:19 UTC

Market Talk

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

9. veebr 2026, 17:41 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

9. veebr 2026, 17:31 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

9. veebr 2026, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

9. veebr 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. veebr 2026, 17:17 UTC

Market Talk

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

9. veebr 2026, 17:16 UTC

Tulu

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

VolitionRX Ltd Prognoos

Hinnasiht

By TipRanks

800% tõus

12 kuu keskmine prognoos

Keskmine 2.25 USD 800%

Kõrge 3 USD

Madal 1.5 USD

Põhineb 3 Wall Streeti analüütiku instrumendi VolitionRX Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi VolitionRX Ltd aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest VolitionRX Ltd

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.